AU2011268072C1 - Antibodies useful in passive influenza immunization - Google Patents

Antibodies useful in passive influenza immunization Download PDF

Info

Publication number
AU2011268072C1
AU2011268072C1 AU2011268072A AU2011268072A AU2011268072C1 AU 2011268072 C1 AU2011268072 C1 AU 2011268072C1 AU 2011268072 A AU2011268072 A AU 2011268072A AU 2011268072 A AU2011268072 A AU 2011268072A AU 2011268072 C1 AU2011268072 C1 AU 2011268072C1
Authority
AU
Australia
Prior art keywords
antibody
fragment
seq
sequence
influenza
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2011268072A
Other languages
English (en)
Other versions
AU2011268072B2 (en
AU2011268072A1 (en
AU2011268072A2 (en
Inventor
Stote Ellsworth
Lawrence M. Kauvar
Krista Maureen Mccutcheon
Minha Park
William Usinger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Trellis Bioscience Inc
Original Assignee
Trellis Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Trellis Bioscience Inc filed Critical Trellis Bioscience Inc
Publication of AU2011268072A1 publication Critical patent/AU2011268072A1/en
Publication of AU2011268072A2 publication Critical patent/AU2011268072A2/en
Assigned to TRELLIS BIOSCIENCE, LLC reassignment TRELLIS BIOSCIENCE, LLC Request for Assignment Assignors: TRELLIS BIOSCIENCE, INC.
Publication of AU2011268072B2 publication Critical patent/AU2011268072B2/en
Priority to AU2017203924A priority Critical patent/AU2017203924B2/en
Application granted granted Critical
Publication of AU2011268072C1 publication Critical patent/AU2011268072C1/en
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Biotechnology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2011268072A 2010-06-17 2011-06-17 Antibodies useful in passive influenza immunization Ceased AU2011268072C1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2017203924A AU2017203924B2 (en) 2010-06-17 2017-06-09 Antibodies useful in passive influenza immunization

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US35597810P 2010-06-17 2010-06-17
US61/355,978 2010-06-17
US201161443103P 2011-02-15 2011-02-15
US61/443,103 2011-02-15
US201161445455P 2011-02-22 2011-02-22
US61/445,455 2011-02-22
PCT/US2011/040982 WO2011160083A1 (en) 2010-06-17 2011-06-17 Antibodies useful in passive influenza immuization

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2017203924A Division AU2017203924B2 (en) 2010-06-17 2017-06-09 Antibodies useful in passive influenza immunization

Publications (4)

Publication Number Publication Date
AU2011268072A1 AU2011268072A1 (en) 2013-01-31
AU2011268072A2 AU2011268072A2 (en) 2013-02-28
AU2011268072B2 AU2011268072B2 (en) 2017-03-09
AU2011268072C1 true AU2011268072C1 (en) 2017-10-19

Family

ID=45348575

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2011268072A Ceased AU2011268072C1 (en) 2010-06-17 2011-06-17 Antibodies useful in passive influenza immunization
AU2017203924A Ceased AU2017203924B2 (en) 2010-06-17 2017-06-09 Antibodies useful in passive influenza immunization

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2017203924A Ceased AU2017203924B2 (en) 2010-06-17 2017-06-09 Antibodies useful in passive influenza immunization

Country Status (12)

Country Link
US (1) US10676520B2 (https=)
EP (1) EP2582721B1 (https=)
JP (1) JP6050747B2 (https=)
KR (1) KR101849738B1 (https=)
CN (2) CN106397584A (https=)
AU (2) AU2011268072C1 (https=)
BR (1) BR112012032185A2 (https=)
CA (1) CA2839421C (https=)
DK (1) DK2582721T3 (https=)
ES (1) ES2687706T3 (https=)
RU (1) RU2635999C2 (https=)
WO (1) WO2011160083A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX367743B (es) 2011-12-05 2019-09-04 Trellis Bioscience Llc Anticuerpos utiles para la inmunizacion pasiva de influenza.
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
CN104968367B (zh) 2012-11-13 2018-04-13 弗·哈夫曼-拉罗切有限公司 抗血凝素抗体和使用方法
MX387277B (es) 2013-03-14 2025-03-12 Contrafect Corp Composiciones basadas en anticuerpos neutralizantes suministrados intranasalmente para eficacia terapéutica aumentada.
US10639370B2 (en) * 2014-02-04 2020-05-05 Contrafect Corporation Antibodies useful in passive influenza immunization, and compositions, combinations and methods for use thereof
JP6712428B2 (ja) 2014-02-04 2020-06-24 コントラフェクト コーポレイション インフルエンザ受動免疫に有用な抗体ならびにその使用のための組成物、組合せおよび方法
CA2940319A1 (en) * 2014-03-20 2015-09-24 Inflarx Gmbh Inhibitors of c5a for the treatment of viral pneumonia
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
EP3374390A1 (en) 2015-11-13 2018-09-19 Visterra, Inc. Compositions and methods for treating and preventing influenza
AU2017222564A1 (en) 2016-02-24 2018-09-06 Visterra, Inc. Formulations of antibody molecules to influenza virus
BR112019000098A2 (pt) * 2016-07-14 2019-04-09 Bioarctic Ab proteína de fornecimento ao cérebro, método de tratamento e/ou profilaxia de distúrbios cerebrais em mamíferos que possuem ou encontram-se em risco de desenvolver o mencionado distúrbio e método de diagnóstico e/ou detecção de distúrbios cerebrais em mamíferos suspeitos de possuir ou que se encontram em risco de desenvolver o mencionado distúrbio
CN111989115A (zh) * 2017-12-29 2020-11-24 财团法人生物技术开发中心 针对流感的通用疫苗
US11780907B2 (en) 2018-01-26 2023-10-10 Regeneron Pharmaceuticals, Inc. Human antibodies to influenza hemagglutinin
US11230593B2 (en) 2019-03-25 2022-01-25 Visterra, Inc. Compositions and methods for treating and preventing influenza

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008028946A2 (en) * 2006-09-07 2008-03-13 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2009079259A2 (en) * 2007-12-06 2009-06-25 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
WO2010010466A2 (en) * 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235708B1 (en) 1998-11-20 2001-05-22 Zymogenetics, Inc Testis-specific cystatin-like protein cystatin T
US20020006656A1 (en) 1999-12-23 2002-01-17 Holloway James L. Zcys5: a member of the cystatin superfamily
AU2003210060B2 (en) 2002-03-22 2010-02-25 Aprogen, Inc. Humanized antibody and process for preparing same
KR20050114225A (ko) 2003-03-07 2005-12-05 머크 앤드 캄파니 인코포레이티드 인플루엔자 바이러스 백신
SG128680A1 (en) * 2003-07-22 2007-01-30 Crucell Holland Bv Binding molecules against sars-coronavirus and uses thereof
RU2366662C2 (ru) * 2003-07-23 2009-09-10 Фуджирибайо Инк. Моноклональное антитело к вирусу типа а гриппа и устройство для иммунного анализа с использованием антитела
US7413868B2 (en) 2003-11-05 2008-08-19 Trellis Bioscience, Inc. Use of particulate labels in bioanalyte detection methods
WO2007134327A2 (en) * 2006-05-15 2007-11-22 Sea Lane Biotechnologies, Llc. Neutralizing antibodies to influenza viruses
RU2448979C2 (ru) * 2006-12-14 2012-04-27 Ридженерон Фармасьютикалз, Инк. Антитела человека к дельта-подобному лиганду-4 человека
JP2011516423A (ja) * 2008-03-28 2011-05-26 シー レーン バイオテクノロジーズ， エルエルシー ウイルス抗原に対する中和分子
TW201019959A (en) * 2008-08-19 2010-06-01 Regeneron Pharma Human antibodies to human RANKL
AU2008365616A1 (en) 2008-12-24 2011-08-11 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to the fusion peptide from hemagglutinin from influenza A viruses and uses thereof
US20130022608A1 (en) 2010-03-26 2013-01-24 Pomona Ricerca S.R.L. FULL-LENGTH IgG IMMUNOGLOBULINS CAPABLE OF RECOGNIZING A HETEROSUBTYPE NEUTRALIZING EPITOPE ON THE HEMAGGLUTININ STEM REGION AND USES THEREOF
CA2807664A1 (en) * 2010-08-12 2012-02-16 Theraclone Sciences, Inc. Anti-hemagglutinin antibody compositions and methods of use thereof
WO2012045001A2 (en) * 2010-09-30 2012-04-05 Vanderbilt University Influenza virus antibodies and immunogens and uses therefor

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008028946A2 (en) * 2006-09-07 2008-03-13 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
WO2009079259A2 (en) * 2007-12-06 2009-06-25 Dana-Farber Cancer Institute, Inc. Antibodies against influenza virus and methods of use thereof
WO2010010466A2 (en) * 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
WO2010010467A2 (en) * 2008-07-25 2010-01-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
EKIERT, DC. ET AL: "Antibody Recognition of a Highly Conserved Influenza Virus Epitope", SCIENCE, vol. 324, no. 5924, 1 April 2009 (2009-04-01), pages 246-251 *
KOSTOLANSKY, F. ET AL: "Antibody response to hidden epitope of influenza A haemagglutinin elicited by anti-idiotypic antibodies.", ACTA VIROLOGICA (AUG 1994), vol. 38, no. 4, pages 215-222 *
PRABHU NAYANA ET AL: "Monoclonal antibodies against the fusion peptide of hemagglutinin protect mice from lethal influenza A virus H5Nl infection" JOURNAL OF VIROLOGY (MAR 2009), vol. 83, no. 6, pages 2553-2562 *
STEEL ET AL "Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain.", MBio (April 2010), Vol 1, No 1, pages 1-9 *
ZIEGLER T ET AL: "Type- and subtype-specific detection of influenza viruses in clinical specimens by rapid culture assay" JOURNAL OF CLINICAL MICROBIOLOGY, vol . 33, no. 2, 1 February 1995 (1995-02-01), pages 318-321 *

Also Published As

Publication number Publication date
CN103209994B (zh) 2016-10-12
AU2011268072B2 (en) 2017-03-09
US20120020971A1 (en) 2012-01-26
WO2011160083A1 (en) 2011-12-22
EP2582721A1 (en) 2013-04-24
CN106397584A (zh) 2017-02-15
CA2839421A1 (en) 2011-12-22
JP2013531993A (ja) 2013-08-15
AU2017203924A1 (en) 2017-07-06
KR101849738B1 (ko) 2018-04-17
EP2582721A4 (en) 2013-11-20
US10676520B2 (en) 2020-06-09
AU2011268072A1 (en) 2013-01-31
RU2013102073A (ru) 2014-07-27
AU2017203924B2 (en) 2019-08-08
BR112012032185A2 (pt) 2016-10-11
RU2635999C2 (ru) 2017-11-17
DK2582721T3 (en) 2018-10-01
EP2582721B1 (en) 2018-08-22
ES2687706T3 (es) 2018-10-26
CN103209994A (zh) 2013-07-17
CA2839421C (en) 2019-12-03
JP6050747B2 (ja) 2016-12-21
KR20130137584A (ko) 2013-12-17
AU2011268072A2 (en) 2013-02-28

Similar Documents

Publication Publication Date Title
AU2011268072C1 (en) Antibodies useful in passive influenza immunization
AU2011373387B2 (en) Neutralizing anti-influenza A virus antibodies and uses thereof
JP6325451B2 (ja) Ａ型インフルエンザに特異的な抗体
EP2793945B1 (en) Antibodies useful in passive influenza immunization
HK1184474B (en) Antibodies useful in passive influenza immunization
HK1184474A (en) Antibodies useful in passive influenza immunization
HK40061503B (zh) 中和抗流感结合分子及其用途
NZ626716B2 (en) Antibodies useful in passive influenza immunization
HK1203410B (en) Antibodies useful in passive influenza immunization
Hufton et al. The Breadth of Cross Sub-Type Neutralisation Activity of a Single Domain Antibody to
EP3122772A1 (en) Chimerization and characterization of a monoclonal antibody with potent neutralizing activity across multiple influenza a h5n1 clades

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 15 JAN 2013

PC1 Assignment before grant (sect. 113)

Owner name: TRELLIS BIOSCIENCE, LLC

Free format text: FORMER APPLICANT(S): TRELLIS BIOSCIENCE, INC.

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 08 MAR 2017

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 08 MAR 2017

DA2 Applications for amendment section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 JUN 2017

DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 29 JUN 2017

FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired